ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs MXN
20.8603
0.30%
Brent Oil
79.63
-0.73%
Bitcoin
107,362.01
4.10%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Pliant Therapeutics Inc (PLRX)

  7. Pliant Therapeutics Inc (PLRX) Noticias

PLRX

Pliant Therapeutics (PLRX)

Pliant Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PLRX
FechaHoraFuenteTítuloSímboloCompañía
02/01/202507:00GlobeNewswire Inc.Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PLRXPliant Therapeutics Inc
21/11/202407:00GlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor EventsNASDAQ:PLRXPliant Therapeutics Inc
18/11/202417:00GlobeNewswire Inc.Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024NASDAQ:PLRXPliant Therapeutics Inc
14/11/202416:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PLRXPliant Therapeutics Inc
07/11/202415:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PLRXPliant Therapeutics Inc
07/11/202415:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
07/11/202415:05GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
06/11/202407:00GlobeNewswire Inc.Pliant Therapeutics to Participate in the Stifel Healthcare ConferenceNASDAQ:PLRXPliant Therapeutics Inc
17/10/202407:00GlobeNewswire Inc.Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024NASDAQ:PLRXPliant Therapeutics Inc
04/10/202416:34Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PLRXPliant Therapeutics Inc
01/10/202415:35GlobeNewswire Inc.Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical AffairsNASDAQ:PLRXPliant Therapeutics Inc
30/09/202415:45GlobeNewswire Inc.Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PLRXPliant Therapeutics Inc
24/09/202407:00GlobeNewswire Inc.Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerNASDAQ:PLRXPliant Therapeutics Inc
10/09/202407:00GlobeNewswire Inc.Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024NASDAQ:PLRXPliant Therapeutics Inc
28/08/202407:00GlobeNewswire Inc.Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of DirectorsNASDAQ:PLRXPliant Therapeutics Inc
26/08/202408:10GlobeNewswire Inc.Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024NASDAQ:PLRXPliant Therapeutics Inc
07/08/202415:05GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
06/08/202415:03GlobeNewswire Inc.Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:PLRXPliant Therapeutics Inc
15/07/202407:00GlobeNewswire Inc.Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple MeasuresNASDAQ:PLRXPliant Therapeutics Inc
12/07/202417:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
13/06/202415:05GlobeNewswire Inc.Pliant Therapeutics Announces Appointment of Steve Krognes to Board of DirectorsNASDAQ:PLRXPliant Therapeutics Inc
06/06/202407:00GlobeNewswire Inc.Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™NASDAQ:PLRXPliant Therapeutics Inc
21/05/202417:50GlobeNewswire Inc.Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International ConferenceNASDAQ:PLRXPliant Therapeutics Inc
14/05/202406:30GlobeNewswire Inc.Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisNASDAQ:PLRXPliant Therapeutics Inc
07/05/202407:00GlobeNewswire Inc.Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™NASDAQ:PLRXPliant Therapeutics Inc
06/05/202415:05GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
27/03/202409:23GlobeNewswire Inc.Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceNASDAQ:PLRXPliant Therapeutics Inc
12/03/202406:30GlobeNewswire Inc.Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisNASDAQ:PLRXPliant Therapeutics Inc
27/02/202415:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PLRXPliant Therapeutics Inc
27/02/202415:03GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PLRX

Su Consulta Reciente

TG
A3KUA6
SaniIkos Financial Holdi...
NYSE
RF-C
Regions Financial
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados